[Form 4] Kiniksa Pharmaceuticals International, plc Insider Trading Activity

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals (KNSA) Form 4 — transactions by Eben Tessari. The filing shows transactions on 09/15/2025 executed under a 10b5-1 plan established April 29, 2024. Tessari acquired 6,500 Class A ordinary shares by exercise of options at an $8.83 exercise price and reported ownership of 6,500 underlying shares from that option. On the same date Tessari sold 16,044 Class A shares at a weighted average price of $36.45 and sold 356 Class A shares at a weighted average price of $37. After these transactions reported beneficial ownership counts include 50,952, 34,908, and 34,552 shares respectively. The option involved is described as fully vested and exercisable.

Positive

• Transactions executed under a 10b5-1 plan established April 29, 2024, providing pre-arranged trade timing
• Option exercise of 6,500 shares at an $8.83 exercise price with the option described as fully vested and exercisable
• Disclosed weighted average sale prices and offer to provide detailed trade-level pricing to SEC staff, enhancing transparency

Negative

• Insider sales totaling 16,400 shares on 09/15/2025 could be perceived as insider liquidity rather than retention
• Beneficial ownership decreased in reported lines to 34,908 and 34,552 shares after the sales

Insights

Corporate Governance Expert

TL;DR: Insider used a pre-established 10b5-1 plan to exercise options and execute multiple open-market sales on 09/15/2025; option is fully vested.

The filing clearly documents that the reporting person implemented transactions under a 10b5-1 plan executed April 29, 2024, which provides an affirmative safe-harbor for timing of trades. The disclosure shows option exercise at $8.83 for 6,500 shares and multiple sales totaling 16,400 shares across two reported sale blocks with weighted average prices of $36.45 and $37. The form explicitly states the option is fully vested and exercisable and includes willingness to provide trade-level price detail to the SEC staff. From a governance perspective, this is routine insider liquidity consistent with a planned trading program; no amendment, repurchase, or other corporate action is disclosed.

Securities Analyst

TL;DR: Material insider sales and an option exercise were executed on a single date under a 10b5-1 plan; sales prices are disclosed as weighted averages.

The form reports an option exercise resulting in acquisition of 6,500 shares at an $8.83 exercise price and contemporaneous open-market sales: 16,044 shares at a weighted average of $36.45 and 356 shares at a weighted average of $37. The filing provides the post-transaction beneficial ownership counts reported by the filer. The disclosure includes price ranges for the executed trades and an offer to provide detailed trade-level pricing to the SEC staff, which supports transparency. These are individual insider transactions and the filing does not include wider company financial metrics or changes to corporate strategy.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Tessari Eben

(Last) (First) (Middle)

23 OLD BOND STREET, THIRD FLOOR

(Street)

LONDON X0 W1S 4PZ

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF OPERATING OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	09/15/2025		M(1)		6,500	A	$8.83	50,952	D
Class A Ordinary Share	09/15/2025		S(1)		16,044	D	$36.45(2)	34,908	D
Class A Ordinary Share	09/15/2025		S(1)		356	D	$37(3)	34,552	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option	$8.83	09/15/2025		M(1)			6,500	(4)	09/16/2029	Class A Ordinary Share	6,500	$0	19,000	D

Explanation of Responses:

1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.

2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $35.83 and $36.74. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

3. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $36.865 and $37.18. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

4. The option is fully vested and exercisable.

	/s/ Aaron Young, Attorney-in-Fact	09/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did KNSA reporting person Eben Tessari make on 09/15/2025?

Tessari exercised an option for 6,500 Class A ordinary shares at an $8.83 exercise price and sold 16,044 shares at a weighted average price of $36.45 and sold 356 shares at a weighted average price of $37, all on 09/15/2025.

Were the 09/15/2025 trades for KNSA executed under a trading plan?

Yes. The filing states the transactions were effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.

What is the exercise price and vesting status of the option reported by the KNSA insider?

The option exercise price was $8.83 for 6,500 shares and the filing states the option is fully vested and exercisable.

How many shares did the reporting person beneficially own after the reported transactions?

The filing reports post-transaction beneficial ownership figures of 50,952, 34,908, and 34,552 shares in the respective lines of the Form 4.

Does the filing provide trade-level pricing for the sales?

The filing discloses weighted average prices and price ranges for the sales and states the reporting person will provide full information regarding the number of shares sold at each price to SEC staff upon request.